Project Grant R01CA298152
Award Date
12/10/24
Completion Date
11/30/29
Dollars Obligated
$663K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Case Western Reserve University to investigate a novel combination therapy approach for acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish the mechanistic role of mTOR hyperactivation as a chemosensitizer for AML. Key objectives include mapping mitochondrial respiratory defects, identifying AML cell susceptibility to metabolic...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $483,760 award, effective April 1, 2025 through March 31, 2030, will enable The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex and genome architecture in AML. Key objectives include deciphering the...
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Trustees of Columbia University in the City of New York provides $2,775,137 to conduct research on the role of aging-related factors in the transformation of pre-leukemic conditions to acute myeloid leukemia (AML). The key objectives are to 1) establish how transcriptional deregulation, inflammatory signals, and stromal niche interactions promote clonal outgrowth of pre-leukemic...
This $101,948 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize germline variants and perform functional validation of variants in a zebrafish model of high-risk pediatric acute myeloid leukemia (AML). The ultimate goal is to determine if predisposition risk factors like germline mutations and viral infections can be mitigated through screening or prophylaxis. The award, effective September 1,...